Finder makes money from featured partners, but editorial opinions are our own. Advertiser disclosure

How to buy ChemoCentryx stock (CCXI)

Buy ChemoCentryx stock in 5 easy steps, view past price performance and learn what’s ahead for the company.

ChemoCentryx is a biotechnology business based in the US. ChemoCentryx shares (CCXI) are listed on the NASDAQ and all prices are listed in US Dollars. ChemoCentryx employs 178 staff and has a trailing 12-month revenue of around $37.3 million.

Our top picks for where to buy ChemoCentryx stock

Our pick for investing by theme

Go to site
  • Trade $0 commission stocks & ETFs with as little as $1
  • Earn up to $300 with qualifying deposits
  • Discover new opportunities with Opto's AI-driven thematic investing system
  • Theme and ETF screener

Top pick for best mobile experience

Go to site
  • Trade $0 commission stocks, ETFs, and options with as little as $1
  • After-hours trading available
  • Earn 4.5% interest on uninvested cash with Gold
  • 24/7 customer support

Alternative pick for crypto trading

Go to site
  • $0 commission trading
  • Instant withdrawals with a 1.75% fee
  • Supports 250+ cryptocurrencies
  • High-yield account earns up to 4.65% APY

How to buy ChemoCentryx stock

  1. Choose a stock trading platform. Use our comparison table
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – CCXI. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Buy ChemoCentryx stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 4 of 4
Name Product USFST Ratings Available asset types Stock trade fee Minimum deposit Cash sweep APY Signup bonus
OPTO
Finder Score: 3.1 / 5: ★★★★★
OPTO
★★★★★
Stocks, ETFs
$0
$0
N/A
Earn up to $300
AI-driven thematic investing, with proprietary research, fractional shares and commission-free stocks and ETFs.
Robinhood
Finder Score: 4.5 / 5: ★★★★★
Robinhood
★★★★★
Stocks, Options, ETFs, Cryptocurrency
$0
$0
4.5%
Get a free stock
Trade stocks, options, ETFs and crypto without commissions and on a user-friendly platform. Plus, a 1% IRA match and no options contract fees.
Uphold
Finder Score: 3.6 / 5: ★★★★★
Uphold
★★★★★
Cryptocurrency
N/A
$0
4.65%
Get $10
Tastytrade
Finder Score: 4.4 / 5: ★★★★★
Tastytrade
★★★★★
Stocks, Options, ETFs, Cryptocurrency, Futures, Treasury Bills
$0
$0
N/A
Get $50-$5,000
Competitive, capped options commissions, with a reliable trading platform designed for serious traders.
loading

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

ChemoCentryx stock price (NASDAQ: CCXI)

Use our graph to track the performance of CCXI stocks over time.

ChemoCentryx shares at a glance

Information last updated 2023-01-01.
52-week range$0.00 - $0.00
50-day moving average $51.50
200-day moving average $31.84
Wall St. target price$52.00
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-2.01

Is it a good time to buy ChemoCentryx stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

ChemoCentryx financials

Revenue TTM $37.3 million
Gross profit TTM $-51,068,000
Return on assets TTM -18.55%
Return on equity TTM -46.96%
Profit margin 0%
Book value $3.32
Market Capitalization $3.7 billion

TTM: trailing 12 months

ChemoCentryx share dividends

We're not expecting ChemoCentryx to pay a dividend over the next 12 months.

ChemoCentryx share price volatility

Over the last 12 months, ChemoCentryx's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".

CCXI.US volatility(beta: 1.23)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ChemoCentryx's is 1.2296. This would suggest that ChemoCentryx's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

ChemoCentryx overview

ChemoCentryx, Inc. , a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis. The company also develops TAVNEOS for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy, and lupus nephritis. In addition, it develops CCX559, an orally administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally administered inhibitor of the chemokine receptor known as CCR9, which has completed Phase I clinical trial for the treatment of inflammatory bowel disease. Further, the company has early-stage drug candidates that targets Th17 driven diseases and CCR6. ChemoCentryx, Inc.

Frequently asked questions

null
What percentage of ChemoCentryx is owned by insiders or institutions?
Currently 12.008% of ChemoCentryx shares are held by insiders and 84.394% by institutions.
How many people work for ChemoCentryx?
Latest data suggests 178 work at ChemoCentryx.
When does the fiscal year end for ChemoCentryx?
ChemoCentryx's fiscal year ends in December.
Where is ChemoCentryx based?
ChemoCentryx's address is: 835 Industrial Avenue, San Carlos, CA, United States, 94070
What is ChemoCentryx's ISIN number?
ChemoCentryx's international securities identification number is: US16383L1061
What is ChemoCentryx's CUSIP number?
ChemoCentryx's Committee on Uniform Securities Identification Procedures number is: 16383L106

More guides on Finder

Ask a question

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Go to site